AstraZeneca Says AZD7442 Antibody Phase 3 Trial Met Primary Endpoint in Preventing Covid-19
20 August 2021 - 8:46AM
Dow Jones News
By Anthony O. Goriainoff
AstraZeneca PLC said Friday that its AZD7442 antibody
significantly reduced the incidence of symptomatic Covid-19 during
the phase 3 trial.
The London-listed pharmaceutical giant said the prophylaxis
trial met its primary endpoint in preventing the illness, and
reduced the risk of developing symptomatic Covid-19 by 77%.
"There were no cases of severe Covid-19 or Covid-19-related
deaths in those treated with AZD7442. In the placebo arm, there
were three cases of severe Covid-19, which included two deaths,"
the company said.
AstraZeneca said data showed that AZD7442 could help people who
may need more than a vaccine to return to their normal lives, and
that preliminary findings from investigators show that the antibody
"neutralizes recent emergent SARS-CoV-2 viral variants, including
the Delta variant."
Write to Anthony O. Goriainoff at
anthony.orunagoriainoff@dowjones.com
(END) Dow Jones Newswires
August 20, 2021 02:40 ET (06:40 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
